Eisai Co., Ltd.: Melanoma trials
The registry lists 10 Melanoma studies with Eisai Co., Ltd. as lead sponsor. 0 are open to participants now and 5 have results posted.
Phase 1 6Phase 2 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid TumorsCompletedNCT05091346Phase 1/2Results posted
- Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic MelanomaCompletedNCT01335009Phase 2Results posted
- An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV MelanomaCompletedNCT01136967Phase 2Results posted
- E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV MelanomaCompletedNCT01133977Phase 1/2Results posted
- Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV MelanomaCompletedNCT01127451Phase 2Results posted
- An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid TumorsCompletedNCT01618136Phase 1/2
- Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III MelanomaTerminatedNCT01605162Phase 2
- A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic MelanomaTerminatedNCT01212276Phase 1
- Safety Study of Human IgM (MORAb-028) to Treat Metastatic MelanomaTerminatedNCT01123304Phase 1
- A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic MelanomaCompletedNCT00121680Phase 1